When was KromaTiD founded?

KromaTiD was founded in 2007 and raised its 1st funding round 5 years after it was founded.

Where is KromaTiD located?

KromaTiD is headquartered in Fort Collins, United States.

How many employees does KromaTiD have?

As of Jul 31, 2026, the latest employee count at KromaTiD is 34.

Is KromaTiD a funded company?

KromaTiD is a funded company, having raised a total of $15.4M across 14 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Aug 06, 2012.

When was the latest funding round of KromaTiD?

KromaTiD's latest funding was a $***** Series C round on Jul 01, 2025, with participation from 1 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.9B in funding in 2026 to date.

Where does KromaTiD rank among its competitors?

KromaTiD ranks 4th amongst 86 active competitors, of which 17 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was KromaTiD, which secured $8M in Jul, 2025.

Who are the top competitors of KromaTiD?

KromaTiD's top competitors include PathogenDX, Agendia and InDevR. Among them, KromaTiD secured the most recent funding round in July, 2025.

KromaTiD - 2026 Company Profile, Funding & Competitors

KromaTiD is a series C company based in Fort Collins (United States), founded in 2007. It operates as a Provider of molecular and genetic tests for detection of disease-causing mutations. KromaTiD has raised $15.4M in funding from Broadoak Capital Partners and First Capital Ventures. The company has 86 active competitors, including 17 funded and 19 that have exited. Its top competitors include companies like PathogenDX, Agendia and InDevR.

Company Details

Provider of molecular and genetic tests for detection of disease-causing mutations, including inversions and translocations, in a single test. Based on its patented Directional Genomic Hybridization (dGH), KromaTiD’s assays generate the sequence, location, and orientation data from single cells, making them ideal for mixed cell population studies. KromaTiD’s research products and services help in a deeper understanding of genetic diseases, including cancers and developmental disorders.

Key Metrics

Founded Year

2007

Location

Fort Collins, United States

Stage

Series C

Total Funding

$15.4M in 14 rounds

Latest Funding Round

Series C, Jul 01, 2025, $*****

Investors

Broadoak Capital Partners & 6 more

Ranked

4^th among 86 active competitors

Employee Count

34 as on Jul 31, 2026

Similar Companies

PathogenDX & 121 more

View KromaTiD's full profile

KromaTiD has raised a total funding of $15.4M over 14 rounds. Its first funding round was on Aug 06, 2012. Its latest funding round was a Series C round on Jul 01, 2025 for $*****. 1 investor participated in its latest round. KromaTiD has 7 institutional investors.

Here is the list of recent funding rounds of KromaTiD:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 01, 2025	2592963	Series C	4763946	2836236	9364602	2394317
Jan 17, 2024	9651971	Series A	1058608	1153842	3501157	9790221
Apr 28, 2021	2809585	Series A	1332063	2577379	Broadoak Capital Partners	9754043

Access funding benchmarks and valuations. Sign up today!

View details of KromaTiD's funding rounds and investors

KromaTiD's employee count trend

KromaTiD has 34 employees as of Jul 26. Here is KromaTiD's employee count trend over the years:

Uncover KromaTiD's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of KromaTiD include PathogenDX, Agendia and InDevR. Here is the list of Top 10 competitors of KromaTiD, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	PathogenDX 2014, Tucson (United States), Series B	Provider of DNA-based pathogen testing kits	$11.6M	Entourage Effect Capital, Altitude Investment Management ... & 11 others	61/100
2nd	Agendia 2003, Irvine (United States), Series F	Provider of genomic diagnostic products for the treatment of cancer	$123M	Athyrium Capital Management, Van Herk Groep ... & 9 others	59/100
3rd	InDevR 2003, Boulder (United States), Acquired	Manufacturer of biotherapeutics, vaccines and diagnostic products	$16M	Adjuvant Capital, BioMerieux & 2 others	57/100
4th	KromaTiD 2007, Fort Collins (United States), Series C	Provider of molecular and genetic tests for detection of disease-causing mutations	$15.4M	NHGRI, Broadoak Capital Partners & 5 others	56/100
5th	Inflammatix 2016, San Francisco (United States), Series E	Provider of diagnostic solutions for systemic infections	$191M	Khosla Ventures, Think.Health & 16 others	53/100
6th	Akonni 2003, Frederick (United States), Series C	Molecular diagnostics and sample prep solutions for high-quality nucleic acid purification	$39.7M	Righton, Choosemaryland.org & 5 others	49/100
7th	GenomeDx Biosciences 2008, San Diego (United States), Series C	Genomic tests for urologic cancers	$69.7M	Merck Global Health Innovation Fund, Calibrium ... & 6 others	46/100
8th	PamGene 1999, Virginia (United States), Series B	Provider of a microarray platform and gene expression profiling system for post-genomic applications	$17.9M	Life Sciences Partners, EQT & 6 others	43/100
9th	BioArray Solutions 2001, New York City (United States), Acquired	Beadchip for biomolecular analysis	$56.8M	Axiom Venture Partners, NGN Capital	42/100
10th	Exiqon 1995, Vedbaek (Denmark), Acquired	Develops LNA-based tools for diagnostics and research	$22.9M	Danske Bank, Teknoinvest & 1 others	41/100